摘要:
It is an object of the present invention to provide a novel therapeutic agent for osteoporosis.HX531 is utilized, which is synthesized as a retinoid X receptor antagonist and has an activity in inhibiting a differentiation into adipocytes. Furthermore, any dosage form containing HX531 as an effective component can be used.
摘要:
An osteoclastgenic inhibitory agent which comprises an interleukin-18 and/or its functional equivalent. The agent can be arbitrarily used as an ingredient for cell culture and agents for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc.